Morgan Stanley Pharming Group N.V. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Pharming Group N.V. stock. As of the latest transaction made, Morgan Stanley holds 2,800 shares of PHAR stock, worth $22,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,800

Previous 2,800 -0.0%

Holding current value

$22,876

Previous $32,000 6.25%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$10.0 - $12.53 $3,000 - $3,759	300 Added 12.0%	2,800 $32,000
Q1 2023 May 15, 2023	SELL	$10.24 - $14.96 $42,485 - $62,069	-4,149 Reduced 62.4%	2,500 $33,000
Q4 2022 Feb 14, 2023	SELL	$9.17 - $13.5 $926 - $1,363	-101 Reduced 1.5%	6,649 $73,000
Q3 2022 Nov 14, 2022	BUY	$6.85 - $12.62 $29,112 - $53,635	4,250 Added 170.0%	6,750 $66,000
Q4 2021 Feb 14, 2022	SELL	$7.58 - $10.1 $363 - $484	-48 Reduced 1.88%	2,500 $22,000

Q3 2021 Nov 15, 2021	BUY	$9.26 - $11.6 $23,594 - $29,556	2,548 New	2,548 $24,000

Others Institutions Holding PHAR

# of Institutions

Shares Held

43K

Call Options Held

Put Options Held

View Full List

About Pharming Group N.V.

Ticker PHAR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,241,400
Market Cap $533M
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the tre...

More about PHAR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account